Oral hairy leukoplakia is a white, ridged patch that forms on the tongue, caused by Epstein-Barr virus replicating inside the surface cells of the mouth. It was originally identified in people with HIV and remains most closely associated with weakened immune systems, but it also turns up in organ transplant recipients, people on certain immunosuppressive drugs, and even some otherwise healthy individuals. The condition is benign and usually painless, yet it carries clinical significance as a visible marker of how well the immune system is functioning.
What It Looks Like
The classic appearance is a white patch with vertical ridges or folds that give it a corrugated, “hairy” look. These patches sit on the lateral and dorsolateral surfaces of the tongue and cannot be scraped off, which immediately distinguishes them from thrush (oral candidiasis). The white coating of thrush wipes away, often revealing a red, raw surface underneath. Oral hairy leukoplakia stays put no matter how much you rub it.1PubMed Central. Oral hairy leukoplakia arising in a patient with hairy cell leukaemia: the first reported case
The lesion can appear on one or both sides of the tongue. Less commonly, it shows up on the inner cheeks or gums. In a series of 45 cases in people without severe immune problems, about 91% of lesions were on the lateral or ventral tongue, and only a handful presented bilaterally.2PubMed. Oral hairy leukoplakia: a series of 45 cases in immunocompetent patients Most people feel nothing at all. Occasionally the texture or appearance bothers someone, or a secondary fungal infection settling into the ridges causes mild discomfort, but pain is uncommon.
The Virus Behind It
Nearly every adult on the planet carries Epstein-Barr virus. After an initial infection, which may cause mono in teenagers and young adults or pass without symptoms entirely, the virus goes dormant and lives quietly in certain immune cells for life. In oral hairy leukoplakia, something different happens: instead of staying latent, EBV begins actively replicating inside the epithelial cells that line the tongue’s surface.
Early research in the mid-1980s established this definitively. Of 20 biopsy specimens from hairy leukoplakia lesions, 19 showed intense staining for the EBV capsid antigen, and DNA analysis confirmed high viral loads with 200 or more copies of viral DNA per cell genome in most samples. Tests for herpes simplex, varicella-zoster, and cytomegalovirus all came back negative.3PubMed. Replication of Epstein-Barr virus within the epithelial cells of oral “hairy” leukoplakia, an AIDS-associated lesion The virus was not just present; it was reproducing in large quantities inside the tongue’s surface cells.
The replication follows a specific pattern within the layers of the tongue’s lining. EBV remains relatively quiet in the deeper layers and shifts into active, lytic replication in the upper layers, the cells that are maturing and about to shed off the surface. Infectious viral particles are released into the saliva as those cells naturally slough away.4PubMed Central. Epstein-Barr Virus and Its Association with Oral Hairy Leukoplakia: A Short Review This is essentially EBV hijacking the tongue’s normal cell turnover to manufacture and spread copies of itself. Only in a minority of people does this productive infection become visible as the characteristic white patches.5PubMed Central. Epstein-Barr Virus and Its Association with Oral Hairy Leukoplakia: A Short Review
Why Immune Status Matters So Much
In a person with a well-functioning immune system, the body typically keeps EBV replication in check. When the immune system is weakened, especially the T-cell surveillance that normally polices viral activity, EBV finds an opening. This is why oral hairy leukoplakia was first described in men with HIV in San Francisco between 1981 and 1984, during the early years of the AIDS epidemic.6PubMed Central. Oral hairy leukoplakia: The role of Epstein–Barr virus, the occurrence in immunocompetent patients, and the malignant transformation potential
The link between immune suppression and oral hairy leukoplakia is dose-dependent. In HIV-positive adults, the risk of developing the lesion climbs steeply as CD4+ T-cell counts drop. People with counts below 200 cells per microliter had roughly seven times the odds of having oral hairy leukoplakia compared to those with higher counts.7PubMed. Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults That same study found additional risk factors: male sex and recreational drug use each roughly doubled the odds. A separate analysis confirmed that low CD4 counts and smoking were both significant risk factors for the condition.8PubMed. Incidence of oral candidiasis and oral hairy leukoplakia in HIV-infected adults in North Carolina
Before effective HIV treatment became widely available, oral hairy leukoplakia was sometimes the first visible sign that a person’s immune system was deteriorating. Finding it in someone who had not been tested for HIV often prompted testing and, in many cases, confirmed a new diagnosis.
Antiretroviral Therapy Changed the Picture
The introduction of combination antiretroviral therapy dramatically reduced how often oral hairy leukoplakia shows up in people living with HIV. A systematic review and meta-analysis found that HIV-positive patients on antiretroviral therapy had significantly lower rates of oral hairy leukoplakia, along with lower rates of several other oral conditions including candidiasis, Kaposi sarcoma, and oral herpes. The authors attributed this to the immune restoration that treatment provides.9PubMed. Impact of highly active antiretroviral therapy on the prevalence of oral lesions in HIV-positive patients: a systematic review and meta-analysis
A broader meta-analysis also found that patients on antiretroviral therapy were about half as likely to present with oral conditions overall, though the researchers noted the certainty of evidence was quite low and called for better-designed primary studies.10PubMed Central. Oral manifestations in HIV-positive individuals under highly active antiretroviral therapy: a systematic review and meta-analysis of prevalence data Interestingly, one study in HIV-positive women found that while antiretroviral therapy reduced other oral lesions, it did not significantly affect the incidence of hairy leukoplakia or warts.11PubMed. Incidence of oral lesions in HIV-1-infected women: reduction with HAART So the picture is encouraging overall but not perfectly uniform across every population studied.
Beyond HIV
Oral hairy leukoplakia is not exclusive to people with HIV. It shows up in anyone whose immune defenses are sufficiently weakened. A report on kidney transplant recipients found the condition in seven patients, six of whom were HIV-negative. All were on aggressive immunosuppressive regimens to prevent organ rejection. The authors concluded that oral hairy leukoplakia is a marker of severe immunosuppression in general, not an HIV-specific phenomenon.12PubMed. Oral hairy leukoplakia in patients with kidney transplantation
More surprising is that the condition increasingly turns up in people who are not severely immunocompromised by any obvious measure. A study of 45 such cases found a median age of 64, and the most common health conditions in the group were ordinary ones: high blood pressure, high cholesterol, and chronic respiratory problems. About a quarter reported no underlying medical conditions at all.13PubMed. Oral hairy leukoplakia: a series of 45 cases in immunocompetent patients
Two factors stood out as possible explanations. The first is localized immunosuppression from steroid inhalers. In a separate review, 28 patients with oral hairy leukoplakia had respiratory conditions requiring long-term inhaler use, suggesting the steroids deposited in the mouth during inhalation may suppress the local immune environment enough to let EBV reactivate.14PubMed. Twenty-first-century oral hairy leukoplakia–a non-HIV-associated entity The second is immunosenescence, the gradual decline in immune function that comes with aging. The median age of 64 in the immunocompetent group lends weight to this idea. Aging does not demolish the immune system the way untreated HIV does, but it may weaken the specific T-cell responses that keep EBV under control.
Getting the Diagnosis Right
A dentist or doctor who has seen oral hairy leukoplakia before can often recognize it on sight, especially when it presents in the classic corrugated pattern on the side of the tongue in a person with known immune issues. The trouble comes with atypical presentations, where the white patch may look flat, faint, or sit in an unusual spot like the cheek or gum line. In these cases, diagnosis relies heavily on ruling out other conditions and confirming the presence of EBV.
Atypical hairy leukoplakia can be confused with thrush, ordinary frictional keratosis (from biting or rubbing), lichen planus, or true leukoplakia with potential for malignant change. One diagnostic clue is that oral hairy leukoplakia does not respond to antifungal treatment, so if a white patch persists after a course of antifungals, the suspicion should shift.15Oral Surgery, Oral Medicine, Oral Pathology. Clinical and histologic spectrum of oral hairy leukoplakia
Under the microscope, a biopsy shows a recognizable set of features: thickening of the surface layers, cells that resemble the “balloon cells” seen in some viral infections, and nuclei with a glassy, ground-glass appearance and clear halos around them. An important distinguishing feature is the absence or near-absence of inflammation in the underlying tissue.16PubMed Central. Diagnosis of Oral Hairy Leukoplakia: The Importance of EBV In Situ Hybridization The definitive confirmation comes from in situ hybridization, a lab technique that detects EBV genetic material directly within the tissue cells. Finding active EBV in the epithelial layers clinches the diagnosis.
Candida fungus is frequently found living on or within the ridged surface of oral hairy leukoplakia, but this is a secondary colonizer rather than a cause. The fungus finds the corrugated texture hospitable, and its presence can muddy the diagnostic waters if a clinician assumes the white patch is just thrush.17PubMed Central. Epstein-Barr Virus and Its Association with Oral Hairy Leukoplakia: A Short Review
Is It Dangerous on Its Own?
Oral hairy leukoplakia itself is benign. It does not transform into cancer, which distinguishes it sharply from ordinary leukoplakia, a white patch that is not EBV-driven and that does carry a small but real risk of progressing to squamous cell carcinoma. The “leukoplakia” in the name is misleading because it invites confusion between two very different conditions. Oral hairy leukoplakia and conventional leukoplakia share only the trait of being white patches in the mouth. Their causes, microscopic appearances, and clinical implications are different.
The danger oral hairy leukoplakia signals is indirect. In someone who has not been diagnosed with HIV or another form of immunosuppression, its appearance should prompt investigation into what is weakening the immune system. For someone already known to have HIV, its emergence or recurrence can suggest that viral control is slipping or that CD4 counts have dropped. It is a clinical signpost more than a disease in itself.
Treatment Options
Because oral hairy leukoplakia is usually painless and poses no cancer risk, many clinicians opt not to treat it at all, focusing instead on managing the underlying cause of immune suppression. When a person starts effective antiretroviral therapy and their immune function improves, the lesion often resolves on its own. But treatment is available for those who find the appearance bothersome, experience discomfort from secondary fungal colonization, or want the lesion gone for other reasons.
Antiviral Medication
High-dose oral valacyclovir, the same drug class used for cold sores and shingles, can clear the lesion by shutting down EBV’s active replication. In a study of 19 cases of HIV-associated oral hairy leukoplakia, the majority resolved with valacyclovir treatment, and EBV replication was terminated.18PubMed. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir Acyclovir, ganciclovir, and other antivirals in the same family have also shown effectiveness. The catch is that the lesion tends to come back after the medication is stopped, because the underlying virus is not eradicated, just suppressed.19JAMA Dermatology. Treatment of Oral Hairy Leukoplakia With Podophyllin
Topical Approaches
Several topical treatments have been tried with varying success. Podophyllin resin, applied directly to the lesion as a 25% solution, has shown striking short-term results. In one case series, all nine treated patients had complete regression of their lesions, most within a week.20PubMed Central. Critical review of topical management of oral hairy leukoplakia Tretinoin (Retin-A) applied daily has also produced healing in roughly 69% of treated patients in one series, compared to about 11% spontaneous regression in untreated patients, but it can cause a burning sensation with prolonged use.21PubMed Central. Critical review of topical management of oral hairy leukoplakia Researchers have also tested combinations of podophyllin with antiviral creams like acyclovir or penciclovir, applied directly to the mouth.22PubMed. A new topical treatment protocol for oral hairy leukoplakia
Surgical Removal
Excision or cryotherapy can physically remove the lesion and, in cases where pain is a problem, resolves symptoms reliably. In a comparison of surgery and acyclovir, all four patients who had pain before surgery experienced relief afterward, and the leukoplakia did not recur in the excised areas. However, new patches appeared in other locations in 10 of the 14 surgical patients within three months.23PubMed. Comparison of the efficacy of surgery and acyclovir therapy in oral hairy leukoplakia This underscores that the virus remains in the tissue regardless of how the visible lesion is handled.
Why the Lesion Keeps Coming Back
Recurrence is the single most frustrating feature of oral hairy leukoplakia treatment. Antivirals, topical agents, and surgery can all make the lesion disappear, but none of them eliminate EBV from the body. The virus retreats to its latent reservoir in immune cells and in the basal layers of the epithelium, waiting for conditions to favor replication again. In the acyclovir comparison study, recurrences were noted in all 12 patients who had responded to the drug within three months of stopping it.24PubMed. Comparison of the efficacy of surgery and acyclovir therapy in oral hairy leukoplakia
This is why improving the underlying immune function remains the most durable approach. For someone with HIV, getting on effective antiretroviral therapy and keeping viral load suppressed is the best path to long-term resolution. For a transplant patient, the lesion may persist as long as immunosuppressive medications are necessary. For an older adult using a steroid inhaler, rinsing the mouth after each use and discussing the lowest effective inhaler dose with a doctor are reasonable steps, though neither has been studied specifically for preventing oral hairy leukoplakia.
Steroid Inhalers and Localized Risk
The connection between inhaled corticosteroids and oral hairy leukoplakia deserves attention because it affects a large group of people who may never think of themselves as immunosuppressed. Millions use steroid inhalers daily for asthma or chronic obstructive pulmonary disease. When the steroid is delivered through the mouth, some of it deposits on the tongue and inner cheeks rather than reaching the lungs. Over time, that local steroid exposure can dampen the immune defenses in the oral mucosa.
Steroid inhalers were the most frequently reported medication class in the immunocompetent case series, used by about 15% of the patients studied.25PubMed. Oral hairy leukoplakia: a series of 45 cases in immunocompetent patients In the larger review of non-HIV-associated cases, 28 patients had respiratory conditions requiring long-term inhaler use, making it the single most common shared feature.26PubMed. Twenty-first-century oral hairy leukoplakia–a non-HIV-associated entity Standard advice for inhaler users already includes rinsing the mouth after each puff to reduce thrush risk. That same practice likely helps reduce oral hairy leukoplakia risk as well, though no one has run a trial on it. If you use a steroid inhaler and notice a white patch on the side of your tongue that does not go away, it is worth having a clinician take a look rather than assuming it is just thrush.
When the Diagnosis Triggers an HIV Test
For a patient who was not previously known to be immunosuppressed, a biopsy-confirmed diagnosis of oral hairy leukoplakia will almost certainly lead a clinician to recommend HIV testing. The association is strong enough that the condition has historically been treated as a sentinel event. Finding it in a young or middle-aged adult with no clear reason for immune suppression is a red flag.
That said, the expanding recognition of cases in older adults and inhaler users means the reflex to assume HIV should be tempered with clinical judgment. In the 45-case immunocompetent series, about a quarter of patients had no relevant medical conditions or medications at all.27PubMed. Oral hairy leukoplakia: a series of 45 cases in immunocompetent patients HIV testing is still appropriate when the condition is discovered, but the result may very well come back negative. The condition is becoming less of a near-certain indicator of HIV and more of a general signal that the local or systemic immune environment has shifted enough for EBV to reactivate.